Comparative Pharmacology
Head-to-head clinical analysis: EVKEEZA versus MODRASTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVKEEZA versus MODRASTANE.
EVKEEZA vs MODRASTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVKEEZA (evinacumab) is a recombinant human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a key regulator of lipoprotein metabolism. Inhibition of ANGPTL3 reduces levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, and other lipoproteins by enhancing the activity of lipoprotein lipase and endothelial lipase, leading to increased clearance of very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL). It also decreases hepatic very low-density lipoprotein production.
Selective antagonist of mineralocorticoid receptors, blocking the binding of aldosterone and other corticosteroids, leading to increased renal excretion of sodium and water while retaining potassium.
Subcutaneous injection of 135 mg once every 2 weeks (every 14 days).
100 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life of 16.8 days (range 10–24 days) in patients with homozygous familial hypercholesterolemia, supporting monthly subcutaneous dosing.
Terminal elimination half-life is 12-15 hours; allows once-daily dosing after steady state achieved within 3-5 days.
Eliminated primarily via reticuloendothelial system metabolism; renal excretion is minimal (<1% unchanged drug); fecal excretion of metabolites accounts for ~99%.
Renal excretion of unchanged drug accounts for 30-40%; biliary/fecal excretion accounts for 50-60%, with 10-20% as glucuronide conjugates.
Category C
Category C
Lipid-lowering Agent
Lipid-lowering Agent